Inside Ziska Pharmaceuticals
our Tizaro products
Tizaro is the brand name for tirzepatide, a once-weekly injectable medicine developed to treat type 2 diabetes mellitus, and has a significant additional effect on body weight.
Unlike older treatments that target only one gut hormone pathway, Tizaro activates two — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) — simultaneously, producing improvements in blood sugar and body weight that go well beyond either pathway alone.
Ziska Pharmaceuticals Ltd. is one of Bangladesh's established pharmaceutical manufacturers, producing quality-assured medicines under DGDA oversight. Tizaro is distributed with a verified cold-chain from facility to dispensing point.
Understanding the science helps set realistic expectations and makes treatment decisions clearer.
GLP-1 is a natural gut hormone released after meals. Tizaro mimics it, stimulating the pancreas to release insulin only when blood glucose is elevated — so there is no unwanted insulin push when sugar is already normal. It also reduces glucagon, preventing excess sugar release from the liver.
GIP is the second gut hormone Tizaro activates. GIP agonism amplifies the weight-reducing signals sent to the brain, reduces the body's energy storage in fat cells, and enhances the metabolic effects of GLP-1 — producing weight loss greater than any GLP-1 drug alone could achieve.
Absorbed subcutaneously over several days, maintaining steady drug levels throughout the week rather than peaks and troughs.
Both GIP and GLP-1 receptors are present in brain areas that control hunger. Activating them reduces food cravings and portion sizes naturally.
Gastric emptying is slowed, meaning meals are digested over a longer period and glucose enters the bloodstream more gradually — flattening post-meal blood sugar spikes.
When blood sugar rises after eating, Tizaro amplifies the pancreatic response; when it falls, insulin returns to baseline — avoiding dangerous hypoglycaemic events.
As appetite decreases and metabolism improves, stored fat is progressively mobilised for energy, leading to the sustained weight reductions seen across the 72-week trial period.
Full SURMOUNT-1 trial data broken down by dose.